Famitinib
Famitinib (pronounced: fa-mi-ti-nib) is a type of tyrosine kinase inhibitor used in the treatment of various types of cancer. It is a novel, potent, and ATP-competitive inhibitor, primarily targeting c-Kit, vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and Flt3.
Etymology
The term "Famitinib" is derived from the combination of the words "Fam" (an abbreviation of the company that developed it, Jiangsu Hengrui Medicine Co., Ltd.) and "tinib" (a common suffix for tyrosine kinase inhibitors).
Pharmacology
Famitinib works by blocking the action of an enzyme known as tyrosine kinase. This enzyme is involved in the growth and spread of cancer cells. By inhibiting this enzyme, Famitinib can slow down or stop the growth of cancer cells.
Clinical Use
Famitinib has been used in clinical trials for the treatment of various types of cancer, including gastric cancer, renal cell carcinoma, and non-small cell lung cancer. It has shown promising results in these trials, with some patients experiencing significant reductions in tumor size and improved survival rates.
Side Effects
Like all medications, Famitinib can cause side effects. The most common side effects include nausea, vomiting, diarrhea, and fatigue. Less common but more serious side effects can include high blood pressure, bleeding, and heart problems.
See Also
External links
- Medical encyclopedia article on Famitinib
- Wikipedia's article - Famitinib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski